Tirzepatide Dosing Schedule: From 2.5mg to 15mg Guide

## Tirzepatide Dosing Schedule: Complete Titration Protocol Tirzepatide dosing follows a structured titration schedule starting at 2.5mg weekly, with increases every 4 weeks. Skipping dose levels or accelerating the timeline significantly increases the risk of gastrointestinal side effects and treatment discontinuation. ## The Standard Tirzepatide Titration Schedule ### Weeks 1-4: 2.5mg (Initiation Dose) This dose exists for one reason: to let your GI system adjust to delayed gastric emptying. It is not a therapeutic dose for weight loss, and that is by design. Think of it as training wheels. What you will probably notice: subtle appetite changes, maybe some mild nausea in the first 48 hours, minimal scale movement (0-3 lbs). All normal. **Practical tip:** Pick your injection day strategically. If your social eating happens on weekends, inject Monday so any nausea peaks mid-week when you are in your routine. ### Weeks 5-8: 5mg (First Therapeutic Dose) This is where things get interesting. At 5mg, GIP and GLP-1 receptor activation reaches levels that actually suppress appetite and alter food reward signaling. In SURMOUNT-1, even the 5mg arm achieved an average 15% body weight loss -- which rivals what [semaglutide 2.4mg delivers](/guides/semaglutide-dosing-schedule-week-by-week-guide). Most patients report that "food noise" drops noticeably at this dose. You stop thinking about your next meal constantly. Portions shrink naturally. Expected cumulative loss by week 8: 5-10 lbs for most people. ### Weeks 9-12: 7.5mg (The Sweet Spot for Many) In our experience, 7.5mg is where a surprising number of patients find their long-term dose. The appetite suppression is strong, side effects have stabilized, and weight loss runs at a steady 1-2 lbs per week. We recommend reassessing at the end of this phase. If you are losing steadily and feeling good, there may be no reason to push higher. More medication is not always better. ### Weeks 13-16: 10mg (Full Therapeutic) At 10mg, metabolic effects are pronounced. Insulin sensitivity improves measurably, visceral fat mobilization accelerates, and most patients report near-complete elimination of food cravings. In SURMOUNT-1, the 10mg arm achieved 19.5% mean body weight loss at 72 weeks. This is the dose where we strongly recommend prioritizing protein -- our [GLP-1 diet guide](/guides/what-to-eat-on-glp1-medications-diet-guide) covers optimal meal planning (aim for 0.7-1g per pound of lean body mass) and maintaining resistance training. The weight you are losing should be predominantly fat. ### Weeks 17-20: 12.5mg Consider this dose if you have genuinely plateaued at 10mg for 4+ weeks despite dietary compliance. Not every patient needs it. ### Week 21+: 15mg (Maximum FDA-Approved) The ceiling dose. In SURMOUNT-1, participants at 15mg achieved a mean 20.9% body weight loss, with over a third losing more than 25%. Powerful -- but roughly 40-50% of patients in clinical practice reach their goals without ever needing 15mg. ## How to Know When to Increase (and When to Stay Put) **Increase your dose when:** - Your current dose is well-tolerated (minimal GI symptoms) - Weight loss has stalled for 3+ consecutive weeks - Your appetite suppression has noticeably weakened - Your provider agrees **Stay at your current dose when:** - You are still losing 0.5-1+ lbs per week - GI side effects have not fully resolved - You are having trouble eating adequate protein - You feel good where you are ## Managing Dose Transitions The first 5-7 days after each increase are typically the hardest. Here is what works: 1. **Inject on a light eating day.** Less food in your stomach means less nausea. 2. **Hydrate aggressively.** Aim for 10+ glasses of water daily during transition weeks. 3. **Keep ginger chews or peppermint tea on hand.** Both help with transient nausea. 4. **Eat small, protein-rich meals** rather than trying to power through large ones. | Dose | What Most Patients Report | |------|--------------------------| | 2.5mg | "Not much different yet, maybe slightly less hungry" | | 5mg | "I actually forget to eat sometimes" | | 7.5mg | "Food cravings are basically gone" | | 10mg | "I eat because I know I should, not because I want to" | | 12.5-15mg | "Strong appetite control, need to focus on getting enough nutrition" | ## Compounded Vial Dosing Calculations If you are using [compounded tirzepatide](/products/tirzepatide-001) from a vial, you need to know your concentration. Our [tirzepatide reconstitution guide](/guides/how-to-reconstitute-tirzepatide-mixing-guide) walks through the full mixing process step by step. **Example: 30mg vial reconstituted with 3ml bacteriostatic water = 10mg/ml** - For 2.5mg: Draw 0.25ml - For 5mg: Draw 0.5ml - For 7.5mg: Draw 0.75ml - For 10mg: Draw 1.0ml - For 15mg: Draw 1.5ml Always verify your calculations with your pharmacist or provider. A dosing error with tirzepatide is not something you want to learn about the hard way. For patients on [high-dose tirzepatide protocols](/guides/tirzepatide-high-dose-15mg-20mg-protocol), accurate reconstitution becomes even more critical. ## What the Timeline Actually Looks Like **Month 1:** Body adjusting, 2-5 lbs lost. This is normal. **Months 2-3:** Active weight loss kicks in, 5-12% of body weight gone. **Months 4-6:** Reaching target dose, continued steady loss. **Months 6-12:** Cumulative loss of 15-22%+ for most patients. **Beyond year 1:** Maintenance phase. Many patients reduce to a lower dose. The patients who do best are the ones who treat the titration schedule as a process, not a race. For patients who need to go beyond 15mg, see our [high-dose tirzepatide protocol guide](/guides/tirzepatide-high-dose-15mg-20mg-protocol). And to understand how tirzepatide compares to other options, read our [tirzepatide vs semaglutide comparison](/guides/tirzepatide-vs-semaglutide-comparison). *This dosing guide is for educational purposes. Always follow your prescribing clinician's specific instructions for your situation.* --- ## References - [SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038). *New England Journal of Medicine*, 2022. - [SURMOUNT-2: Tirzepatide for Treatment of Obesity in Type 2 Diabetes](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01200-X/fulltext). *The Lancet*, 2023. - [Mounjaro (tirzepatide) Prescribing Information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf). *Eli Lilly and Company*, 2024.